Related Experiment Video
Updated: May 31, 2026

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)
Published on: April 7, 2021
Surfactant therapy for acute lung injury and acute respiratory distress syndrome
Krishnan Raghavendran1, D Willson, R H Notter
1Division of Acute Care Surgery, Department of Surgery, University of Michigan Health System, 1500 East Medical Center Drive, 1C340A-UH, SPC 5033, Ann Arbor, MI 48109-5033, USA. kraghave@umich.edu
Abstract:
This article examines exogenous lung surfactant replacement therapy and its usefulness in mitigating clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). Surfactant therapy is beneficial in term infants with pneumonia and meconium aspiration lung injury, and in children up to age 21 years with direct pulmonary forms of ALI/ARDS. However, extension of exogenous surfactant therapy to adults with respiratory failure and clinical ALI/ARDS remains a challenge. This article reviews clinical studies of surfactant therapy in pediatric and adult patients with ALI/ARDS, focusing on its potential advantages in patients with direct pulmonary forms of these syndromes.
More Related Videos
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Breathing
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:
Respiratory Syncytial Virus Disease
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...

